APYX vs. ICAD, CODX, TTOO, PYPD, TELA, NPCE, DCTH, RCEL, TLSI, and OBIO
Should you be buying Apyx Medical stock or one of its competitors? The main competitors of Apyx Medical include iCAD (ICAD), Co-Diagnostics (CODX), T2 Biosystems (TTOO), PolyPid (PYPD), TELA Bio (TELA), NeuroPace (NPCE), Delcath Systems (DCTH), AVITA Medical (RCEL), TriSalus Life Sciences (TLSI), and Orchestra BioMed (OBIO). These companies are all part of the "surgical & medical instruments" industry.
Apyx Medical (NASDAQ:APYX) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends.
Apyx Medical has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, iCAD has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
iCAD has lower revenue, but higher earnings than Apyx Medical. iCAD is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks.
iCAD has a net margin of -15.20% compared to Apyx Medical's net margin of -45.20%. iCAD's return on equity of -14.00% beat Apyx Medical's return on equity.
55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 24.6% of iCAD shares are held by institutional investors. 13.1% of Apyx Medical shares are held by insiders. Comparatively, 12.0% of iCAD shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
iCAD received 151 more outperform votes than Apyx Medical when rated by MarketBeat users. Likewise, 62.81% of users gave iCAD an outperform vote while only 61.60% of users gave Apyx Medical an outperform vote.
Apyx Medical presently has a consensus target price of $6.17, suggesting a potential upside of 273.74%. iCAD has a consensus target price of $5.00, suggesting a potential upside of 244.83%. Given Apyx Medical's higher probable upside, research analysts plainly believe Apyx Medical is more favorable than iCAD.
In the previous week, Apyx Medical had 1 more articles in the media than iCAD. MarketBeat recorded 4 mentions for Apyx Medical and 3 mentions for iCAD. Apyx Medical's average media sentiment score of 1.19 beat iCAD's score of 0.79 indicating that Apyx Medical is being referred to more favorably in the media.
Summary
iCAD beats Apyx Medical on 9 of the 17 factors compared between the two stocks.
Get Apyx Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for APYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apyx Medical Competitors List
Related Companies and Tools
